KLAB is marketing its generic products in the various
therapeutic segments through its sales team. KLAB products
are manufactured in WHO-GMP facilities. KLAB has contract
manufacturing agreement with Indian and International
companies for some of their products.
KLab has focus on Chiral synthesis. Chiral synthesis has
become important in research and industry due to the
pathways increased need for enantiopure chiral durgs. This
leads to strong and fast growing range of new chiral
building blocks, chiral catalysts and the increased use of
chiral biotransformation in organic synthesis.
KLab is one of the pioneers in India in KLAB is a pioneer in
the Indian Oncology formulations market. It has one of the
widest range of Oncology formulations, which are
manufactured at KLAB owned WHO-GMP approved facility at
KLAB manufactures tablets, capsules, powder and liquid
KLAB's oncology products are now registered in more than 30
countries in Africa, Latin America, CIS and South East Asia.
In India KLAB has a dedicated Oncology task force which
covers Oncologists and Oncology Institutions across the
length and breadth of India. Further, KLAB supplies finished
ONCO formulations to a large number of Indian Companies.